Floatz logo

Therapeutic Asset Ratings

234 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Panobinostat
Breast Cancer
Dana-Farber Cancer InstituteP2B (59)
Cosibelimab
Cutaneous Squamous Cell Carcinoma
Dana-Farber Cancer InstituteP4B (58)
Copanlisib
Refractory Diffuse Large B-Cell Lymphoma
Dana-Farber Cancer InstituteP2B (58)
Hyaluronidase zzxf
Estrogen Receptor-positive Breast Cancer
Dana-Farber Cancer InstituteP2B (58)
Ipilimumab
Genitourinary Cancer
Dana-Farber Cancer InstituteP2B (58)
Ipilimumab
Hodgkin Lymphoma
Dana-Farber Cancer InstituteP2B (58)
Olaparib
Clinical Stage III Cutaneous Melanoma AJCC v8
Dana-Farber Cancer InstituteP2B (58)
Palbociclib
Ewing Sarcoma
Dana-Farber Cancer InstituteP2B (57)
Metformin
Endometrial Cancer
Dana-Farber Cancer InstituteP2CCC (55)
Olaparib
Metastatic Melanoma
Dana-Farber Cancer InstituteP2CCC (55)
Cosibelimab
Skin Cancer
Dana-Farber Cancer InstituteP4CCC (54)
flt3 ligand
Metastatic Melanoma
Dana-Farber Cancer InstituteP2CCC (54)
Recombinant Human Interleukin-2
Leukemia
Dana-Farber Cancer InstituteP2CCC (54)
Relugolix
Prostatic Neoplasms
Dana-Farber Cancer InstituteP2CCC (54)
Atezolizumab
Residual Cancer
Dana-Farber Cancer InstituteP2CCC (53)
Belzutifan
Gynecologic Cancer
Dana-Farber Cancer InstituteP2CCC (53)
Belzutifan
Ovarian Carcinoma
Dana-Farber Cancer InstituteP2CCC (53)
Belzutifan
Uterine Cancer
Dana-Farber Cancer InstituteP2CCC (53)
Belzutifan
Vaginal Cancer
Dana-Farber Cancer InstituteP2CCC (53)
Belzutifan
Vulvar Cancer
Dana-Farber Cancer InstituteP2CCC (53)
Casdatifan
Kidney Neoplasm
Dana-Farber Cancer InstituteP2CCC (53)
Ciltacabtagene Autoleucel
Smoldering Multiple Myeloma
Dana-Farber Cancer InstituteP2CCC (53)
Cyclophosphamide
PD-L1 Negative
Dana-Farber Cancer InstituteP2CCC (53)
Dostarlimab
Deleterious PALB2 Gene Mutation
Dana-Farber Cancer InstituteP2CCC (53)
Dostarlimab
Germline BRCA1 Gene Mutation
Dana-Farber Cancer InstituteP2CCC (53)
Showing 51 to 75 of 234 assets
PreviousPage 3 of 10Next